{
    "clinical_study": {
        "@rank": "55182", 
        "arm_group": [
            {
                "arm_group_label": "Huachansu + TACE", 
                "arm_group_type": "Experimental", 
                "description": "Patients in this arm will receive Huachansu tablets each 3 and 3 times a day orally, as well as transcatheter arterial chemoembolization every 4 weeks, until progression of disease or adverse effects leading to termination of treatment. Each 4-week period is one cycle of treatment."
            }, 
            {
                "arm_group_label": "TACE", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients in this arm will receive transcatheter arterial chemoembolization every 4 weeks, until progression of disease or adverse effects leading to termination of treatment. Each 4-week period is one cycle of treatment."
            }
        ], 
        "brief_summary": {
            "textblock": "Primary Outcome Measures:\n\n      - To compare the progression free survival(PFS) in patients with unresectable hepatocellular\n      carcinoma(HCC) treated with transcatheter arterial chemoembolization(TACE) with or without\n      Huachansu, and the correlation between PFS and expression of peripheral Na+/K+-ATPase \u03b13\n      family.\n\n      Secondary Outcome Measures:\n\n      - To compare the overall survival(OS), objective response rate(ORR), and side effects of\n      treating HCC with TACE plus Huachansu or TACE alone.\n\n      Exploratory Outcome Measures:\n\n      - To evaluate the correlation between prognosis and expression of peripheral Na+/K+-ATPase\n      \u03b13 family."
        }, 
        "brief_title": "Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase", 
        "condition": "Carcinoma, Hepatocellular", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subjects 18-75 years of age.\n\n          -  Diagnosis of hepatocellular carcinoma. Biopsy is the preferred method of diagnosis\n             (option 1). As far as clinically possible, the results of a biopsy should be obtained\n             to confirm the diagnosis prior to the initiation of investigational product\n             administration.. Non-biopsy criteria are allowed in cases where a biopsy result is\n             unavailable and a biopsy procedure is not clinically indicated (option 2).    (Option\n             1: Biopsy-proven HCC (histology or cytology); Option 2 - patient must fulfill the\n             following criteria: i. Radiological evidence of HCC showing lesion arterial\n             hypervascularity and venous phase washout by either dynamic (triple-phase),\n             contrast-enhanced computed tomography of the abdomen OR dynamic (triple-phase)\n             contrast (gadolinium)-enhanced MRI, AND ii. Serology positive for hepatitis B or C,\n             AND iii. Alpha fetoprotein > 400 \u03bcg/L at the time of diagnosis.)\n\n          -  No metastasis outside liver.\n\n          -  Unable or unwilling to receive radical surgery.\n\n          -  No prior transcatheter arterial chemoembolization.\n\n          -  No prior treatment of bufalins including Huachansu.\n\n          -  At least one measurable untreated lesion. All subjects must have at least one\n             measurable lesion unidimensionally by CT or MRI scan, according to modified RECIST\n             for HCC, that has not been previously treated with surgery, irradiation,\n             radiofrequency ablation, percutaneous ethanol or acetic acid injection, or\n             cryoablation.\n\n          -  Cirrhotic status of Child-Pugh Class A or B.\n\n          -  Adequate hematologic function with absolute neutrophil counts \u2265 1.5\u00d7109 /L, platelet\n             count \u2265 50 x 109/L, and hemoglobin \u2265 85 g/L.\n\n          -  Signed Written Informed Consent.\n\n          -  Subjects who have a life expectancy of at least 3 months.\n\n          -  Women of childbearing potential (WOCBP) must be using an adequate method of\n             contraception to avoid pregnancy throughout the study that the risk of pregnancy is\n             minimized.\n\n        Exclusion Criteria:\n\n          -  Previously treated target lesion with irradiation, TACE, radiofrequency ablation,\n             percutaneous ethanol or acetic acid injection, or cryoablation.\n\n          -  Cirrhotic status of Child-Pugh Class C.\n\n          -  Severe diseases of heart, liver, kidney, etc that may cause inadequate organ\n             functions\n\n          -  History of other malignant tumor in 5 years.\n\n          -  Pregnant or lactating women.\n\n          -  Mentally disordered.\n\n          -  Participation of other clinical trials within a month."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01715532", 
            "org_study_id": "2012.01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Huachansu + TACE", 
                "intervention_name": "Huachansu", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Huachansu + TACE", 
                    "TACE"
                ], 
                "intervention_name": "TACE", 
                "intervention_type": "Other", 
                "other_name": "transcatheter arterial chemoembolization"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Huachansu", 
            "Na+/K+-ATPase \u03b13", 
            "transcatheter arterial chemoembolization", 
            "randomized controlled trial"
        ], 
        "lastchanged_date": "October 24, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Fudan University Shanghai Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase II Study of Huachansu for Treatment of Advanced Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase", 
        "overall_official": {
            "affiliation": "Fudan University", 
            "last_name": "Hao Chen, MD, Ph D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: State Administration of Traditional Chinese Medicine of the People's Republic of China"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Progression free survival", 
            "safety_issue": "No", 
            "time_frame": "From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01715532"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Hao Chen", 
            "investigator_title": "Associated Professor, MD, Ph D", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Overall survival", 
            "safety_issue": "No", 
            "time_frame": "From date of randomization until the date of death, assessed up to 100 months."
        }, 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}